Supplementary Table 1. Treatment-emergent adverse events stratified by baseline hostility (safety sample)

Short-term studies, n (%)	With hostility (P7 score ≥2)			Without hostility (P7 score <2)		
	Placebo (n=257)	Brexpiprazole 2 mg (n=261)	Brexpiprazole 4 mg (n=271)	Placebo (n=109)	Brexpiprazole 2 mg (n=105)	Brexpiprazole 4 mg (n=91)
At least one TEAE	150 (58.4)	154 (59.0)	163 (60.1)	64 (58.7)	56 (53.3)	54 (59.3)
TEAEs occurring in ≥5% of patients in any brexpiprazole group						
Headache	30 (11.7)	25 (9.6)	33 (12.2)	12 (11.0)	11 (10.5)	8 (8.8)
Insomnia	31 (12.1)	29 (11.1)	26 (9.6)	13 (11.9)	12 (11.4)	16 (17.6)
Akathisia	13 (5.1)	13 (5.0)	22 (8.1)	4 (3.7)	4 (3.8)	3 (3.3)
Agitation	21 (8.2)	16 (6.1)	20 (7.4)	11 (10.1)	11 (10.5)	6 (6.6)
Schizophrenia	25 (9.7)	16 (6.1)	15 (5.5)	13 (11.9)	1 (1.0)	6 (6.6)
Weight increased	5 (1.9)	9 (3.4)	15 (5.5)	1 (0.9)	3 (2.9)	1 (1.1)
Nausea	8 (3.1)	13 (5.0)	5 (1.8)	5 (4.6)	3 (2.9)	2 (2.2)

P7, Positive and Negative Syndrome Scale hostility item; TEAE, treatment-emergent adverse event.

Supplement to: Effect of brexpiprazole on agitation and hostility in patients with schizophrenia: post hoc *analysis of short- and long-term studies*